Order Article Reprints

Bortoletto R, Basaldella M, Candolo A, Garzitto M, Comacchio C, Curcio F, Fabris M, Fornasaro S, Piscitelli F, Sepulcri O, et al. The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults. Clinical and Translational Neuroscience. 2024; 8(2):20. https://doi.org/10.3390/ctn8020020

Bortoletto, Riccardo, Marta Basaldella, Anna Candolo, Marco Garzitto, Carla Comacchio, Francesco Curcio, Martina Fabris, Stefano Fornasaro, Fabiana Piscitelli, Orietta Sepulcri, and et al. 2024. "The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults" Clinical and Translational Neuroscience 8, no. 2: 20. https://doi.org/10.3390/ctn8020020

Bortoletto, R., Basaldella, M., Candolo, A., Garzitto, M., Comacchio, C., Curcio, F., Fabris, M., Fornasaro, S., Piscitelli, F., Sepulcri, O., Balestrieri, M., & Colizzi, M. (2024). The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults. Clinical and Translational Neuroscience, 8(2), 20. https://doi.org/10.3390/ctn8020020